One such pathway is SREBF1 (also known as SREBP1), which is hyperactivated upon Lats2 depletion in both mammary tumors (ingenuity activation z-score 0.64; P-value of overlap 3.6 × 10−8) and mouse livers (Aylon et al, 2016). Here, LATS2 is linked to breast cancer.